Becker's ASC Review

Nov_Dec_2017_ASC (1)

Issue link: https://beckershealthcare.uberflip.com/i/912067

Contents of this Issue

Navigation

Page 61 of 63

62 HEALTHCARE NEWS ADVERTISINGINDEX Note: Ad page number(s) given in parentheses ADVERTISER Tenet Explores Strategic Options, Including Sale: 9 Things to Know By Molly Gamble S hares of Tenet Healthcare surged 14 percent Sept. 11, shortly aer e Wall Street Journal reported the Dallas-based hospital operator hired banking advisors to evaluate strategic options, including a sale of the company. Aer two board members abruptly quit Tenet's governing body over "irreconcilable differences" in mid-August, they made it known their employer and Tenet's largest stakeholder — Glenview Capital Man- agement — "may evaluate other avenues to be a constructive owner of Tenet" on or aer Sept. 1. News of meetings involving banking advisors appears to be the latest progression of that assurance. Here are nine things to know about the most recent development for the 77-hospital chain. 1. Tenet is in the early phases of work with the advisors, who were brought on to explore a number of strategic options, including the sale of assets, divisions or the entire company. e Wall Street Jour- nal report, which broke the news, is based on accounts from "people familiar with the matter." Tenet stock shot up aer hours, when the WSJ ran the story. 2. Last week, in a presentation he made at the Baird 2017 Global Healthcare Conference, Tenet CEO Trevor Fetter shared plans to divest eight hospitals in four U.S. markets as well as nine facilities in the United Kingdom. ose eight U.S. hospitals include two in Philadelphia: Hahnemann University Hospital and St. Christopher's Hospital for Children, the sale of which Becker's Hospital Review re- ported separately. 3. At the Wells Fargo Health Care conference, also last week, Mr. Fetter discussed continuing to divest facilities, but did not mention the pos- sibility of a company sale during his appearance, according to CNBC. 4. Mr. Fetter, 57, stepped down from his positions as CEO and direc- tor Oct. 23, aer leading Tenet since 2003. On Aug. 31, the company initially announced Mr. Fetter would depart by March 15, 2018, or when the company appointed a successor. Ronald A. Rittenmeyer, Tenet executive chairman, is serving as CEO during the company's executive search. 5. Tenet made two other corporate changes when announcing Mr. Fetter's departure: a "refreshment" of its board and a poison pill de- signed to protect $1.7 billion in net operating loss carry forwards. 6. Tenet began the refreshment process for its board with the appoint- ment of Mr. Rittenmeyer, who previously served as independent lead director. Tenet did not specify how many board members will be affected by the refreshment process, though it "expects to further en- hance the board's expertise in areas directly relevant to the company's business." 7. Under the poison pill, if any person or entity acquires 4.9 percent or more of Tenet stock, all holders of rights issued under the plan are entitled to acquire shares of common stock with a 50 percent discount. e plan is scheduled to expire aer Tenet's 2018 annual meeting of stockholders. 8. e company is under pressure from its largest shareholder, Glenview Capital Management. When two Tenet board members, both employed by Glenview, resigned over what they described as "irreconcilable differ- ences," they made it known that Glenview would possibly "evaluate other avenues" to be a constructive owner of Tenet on or aer Sept. 1. 9. Tenet's debt load has tripled in five years to $15 billion. e com- pany includes 77 hospitals and 130,000 employees. e company ended the second quarter of this year with a net loss of $56 million, compared to a net loss of $44 million in the same period of the year prior. n AAAHC. www.aaahc.org/achieve (pg. 11) Arthrex. ad.arthrex.com/gs4k (pgs. 2-3) ASCOA. development@ascoa.com / www.ascoa.com / (866)982-7262 (pg. 26) ASCs Inc. info@ascs-inc.com / www.ascs-inc.com / (760)751-0250 (pg. 41) Boston Scientific. endoscopysolutions@bsci.com / www.bostonscientific.com/endoscopysolutions (pg. 63) CONMED. conmed.com/visualization / (800)237- 0169 (pg. 25) CRH Anesthesia. info@crhanesthesia.com / www. crhanesthesia.com / (866)699-5333 (pgs. 42 - 45) Cygnus Medical. www.cygnusmedical.com / (800)990-7489 (pg. 29) eSutures. info@esutures.com / esutures.com / (888)416-2409 (pg. 34) gMed. www.gmed.com / (954)541-8240 (pgs. 18 - 21) IBSS. info@ibss.net / www.ibss.net / (803)736-5595 ext. 153 (pg. 23) OrthAlign. info@orthalign.com / orthalign.com / (866)582-0879 (pg. 47) National Medical Billing Services. nationalascbilling.com / (866)948-8001 (pg. 7) Paradigm Spine. april.spillane@paradigmspine. com / (561)573-7882 (pg. 9) ShareSafe Solutions. sharesafesolutions.com / (251)378-5885 (pgs. 36 - 39) Smith&Nephew. www.naviorobotics.com (pg. 13) VMG Health. info@vmghealth.com / vmghealth. com (pg. 64)

Articles in this issue

Links on this page

view archives of Becker's ASC Review - Nov_Dec_2017_ASC (1)